Analgesia with fentanyl and midazolam during interventional radiologic liver tumor ablation by catheter-based radiotherapy-safety and risk factors.

Analgesia with fentanyl and midazolam during interventional radiologic liver tumor ablation by catheter-based radiotherapy-safety and risk factors. - Analgesia with fentanyl and midazolam

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032468

Enrollment

1000

Registered

2023-10-25

Start date

2023-11-13

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0 C78.7

Interventions

Group 1: To retrospectively record the clinical findings of patients with liver tumors who underwent analgesia during interventional radiological tumor ablation.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who have undergone local ablation therapy with catheter-based radiotherapy under analgesia for one or more liver tumors.

Exclusion criteria

Exclusion criteria: Patients who have not undergone local ablation therapy with catheter-based radiotherapy under analgesia due to one or more liver tumors.

Design outcomes

Primary

Measure	Time frame
Of all identified patients who received catheter-based radiotherapy for liver tumors, age, gender, BMI, ASA, comorbidities, smoking history, procedural characteristics (duration of procedure, volume irradiated, number of catheters), dose of fentanyl/midazolam, and procedural co-factors (bleeding, allergic reaction) documented after the primary procedure will be collected and analyzed anonymously. July 01, 2017 marks the date of establishment of catheter-based radiotherapy at LMU Hospital.	—

Measure

Time frame

Of all identified patients who received catheter-based radiotherapy for liver tumors, age, gender, BMI, ASA, comorbidities, smoking history, procedural characteristics (duration of procedure, volume irradiated, number of catheters), dose of fentanyl/midazolam, and procedural co-factors (bleeding, allergic reaction) documented after the primary procedure will be collected and analyzed anonymously. July 01, 2017 marks the date of establishment of catheter-based radiotherapy at LMU Hospital.

—

Secondary

Measure	Time frame
Vital Sign Fluctuation (SpO2 <90% and/or BP reduction of 20% from baseline) is considered a potential event.	—

Countries

Germany

Contacts

Public ContactMax Seidensticker

LMU München

max.seidensticker@med.uni-muenchen.de+4989440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026